Clinical trials for Acute myeloid leukemia with 11q23 abnormalities
36 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington · PI: Anna Halpern, MD
- RECRUITINGPhase 3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center · PI: Naveed Ali, MD
- RECRUITINGPhase 1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPhase 1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Branko Cuglievan, MD
- RECRUITINGPhase 1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · PI: Qiubai Li, Professor
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
- RECRUITINGNCT06458244The Efficacy of Allo-HSCT in ND HR-CBF-AMLRuijin Hospital · PI: Yang Shen, MD, PhD
- RECRUITINGPhase 1NCT05886049Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A GeneNational Cancer Institute (NCI) · PI: Alice S Mims
- RECRUITINGPHASE1, PHASE2NCT06299462PTCy and ATG for MSD and MUD TransplantsInstituto Nacional de Cancer, Brazil · PI: Leonardo J Arcuri, MD, PhD
- RECRUITINGPhase 3NCT06387069A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaHutchmed · PI: Xiaojun Huang, Doctor
- RECRUITINGPhase 1NCT06222580SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationUma Borate · PI: Uma M Borate, MD, MS
- ACTIVE NOT RECRUITINGPhase 1NCT06034470Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsFred Hutchinson Cancer Center · PI: Jacob Appelbaum, MD, PhD
- RECRUITINGPhase 1NCT06034275Study of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesVincerx Pharma, Inc. · PI: Vincerx Study Director
- ENROLLING BY INVITATIONNCT05212103PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9Turku University Hospital · PI: Anne Roivainen
- RECRUITINGNCT05772559Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction StudiesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPhase 2NCT05401097IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)Alice Mims · PI: Alice S Mims, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05316701Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesOrca Biosystems, Inc.
- RECRUITINGPhase 1NCT04872478Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALMeryx, Inc. · PI: Melinda Pauley, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04763928Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxGruppo Italiano Malattie EMatologiche dell'Adulto
- ACTIVE NOT RECRUITINGNCT04635384Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme TestCareDx · PI: Nishant Dwivedi, MD/PhD
- RECRUITINGPhase 2NCT04888741Methods of T Cell Depletion Trial (MoTD)University of Birmingham · PI: Ronjon Professor Chakraverty
- ACTIVE NOT RECRUITINGPhase 3NCT04229979Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Sellas Life Sciences Group · PI: Dragan Cicic Chief Development Officer, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03953898Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationNational Cancer Institute (NCI) · PI: Rory M Shallis
- RECRUITINGPHASE1, PHASE2NCT04128748Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · PI: Musa Yilmaz
- ACTIVE NOT RECRUITINGPhase 1NCT04013685Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesOrca Biosystems, Inc.
- RECRUITINGPHASE1, PHASE2NCT04065399A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationSyndax Pharmaceuticals · PI: Angela R Smith, M.D.
- RECRUITINGPHASE1, PHASE2NCT04067336First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT04068597Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesCellCentric Ltd. · PI: Tim Somervaille
- RECRUITINGPhase 1NCT03802695A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesOrca Biosystems, Inc. · PI: James S McClellan, MD, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03862157Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Nicholas Short
- RECRUITINGPhase 2NCT03586609Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Tapan M Kadia
- ACTIVE NOT RECRUITINGPhase 2NCT03286530Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLMassachusetts General Hospital · PI: Gabriell Hobbs, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02250937Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer Center · PI: Uday R Popat
- ACTIVE NOT RECRUITINGPhase 3NCT01371981Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNational Cancer Institute (NCI) · PI: Richard Aplenc